TG Therapeutics Stock Up 4% on Bold MS Drug Revenue Outlook for 2026

NEW YORK, August 21 —

TG Therapeutics, Inc. (TGTX) issued bold 2026 revenue guidance anchored to BRIUMVI, with total trailing sales already up 70.3% YoY to $800mn and the stock priced at just 18.3x forward earnings.

18x Forward Earnings on 70% Revenue Growth Is the Mismatch Most Are Missing

Strip out the noise and the valuation is stark. A company generating $800mn in trailing revenue, growing that base at 70.3% YoY, with $59mn in free cash flow and $2.74 in trailing EPS is priced at 18.3x forward earnings, a multiple that implies the market expects the growth rate to collapse, not continue. That's not a growth premium; that's a show-me price. Either the street is right that execution risk is severe, or TGTX is the most under-owned growth setup in mid-cap healthcare right now. The stock's 4% gain Thursday didn't resolve that question; it just restarted the debate.

27.7% of the Float Is Betting Against $59mn in Free Cash Flow

Short interest at 27.7% of float is unusually heavy for a profitable company compounding revenue at this pace. The shorts aren't disputing the trailing numbers. That revenue base, $59mn in FCF, and $2.74 EPS are hard to argue with. What they're betting on is forward execution: that BRIUMVI's at-home adoption curve flattens before management's 2026 assumptions are met. The 5-session losing streak that preceded Thursday's reversal shows that thesis had real price momentum. A single quarter of BRIUMVI revenue that comes in ahead of the implied guidance rate compresses that short base fast, and the gap-down visible in the chart is exactly the kind of overshoot that creates those setups.

At-Home Infusion Removes the Bottleneck Most MS Drug Coverage Ignores

The at-home administration pathway is what wire coverage consistently underweights. Most alternative MS infusion therapies require clinic visits, a scheduling friction that slows new patient starts and erodes adherence over time. A drug that reaches the patient at home removes that bottleneck entirely, accelerating adoption curves independent of clinical differentiation. That structural edge is the actual basis for retail analysts citing "multi-billion" BRIUMVI potential. It is a distribution moat, not just a clinical one, and distribution moats in specialty pharma are stickier than they look at launch.

One Number Will Settle Whether Bold Guidance Was Earned or Premature

Watch the BRIUMVI net product revenue line in the next quarterly filing, not total revenue, which can be obscured by licensing or collaboration items. A deceleration in YoY growth from the current 70%-plus pace, or any downward revision to 2026 full-year guidance, confirms the short thesis and almost certainly retests the stock's floor. That forward multiple leaves almost no buffer: at this valuation, any miss gets repriced as a structural slowdown, not a one-quarter noise event. Management calling the 2026 outlook "bold" is either the right kind of confident or the wrong kind. Use the DCF calculator to stress-test the growth assumptions before the next earnings call answers that.

Pull TGTX's full financial profile and generate a custom Basis Report at basisreport.com/stock/tgtx.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.